8-K
filed May 29, 2026, 4:05 PM ET
ticker NMRA
CIK 0001885522
other material
confidence high
sentiment neutral
materiality 0.15
Neumora Therapeutics annual meeting elects directors, ratifies auditor, approves executive compensation
Neumora Therapeutics, Inc.
- Directors Paul L. Berns, Matthew Fust, David Piacquad elected with ~126M, ~125M, ~127M votes for, respectively; ~25M broker non-votes.
- Ernst & Young ratified as independent auditor for FY 2026 with 157.6M votes for, 53.6K against.
- Advisory vote on named executive officer compensation approved: 132.0M for, 420.9K against, 25.0M broker non-votes.
- Advisory vote on say-on-pay frequency: majority selected one year; company will hold annual advisory votes on executive compensation.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Neumora Therapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2029 annual meeting at the 2026-05-27 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 1. The election of three Class III directors to hold office until the 2029 annual meeting of stockholders and until their respective successor is elected and qualified or until their earlier death, resignation, disqualification or removal. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Paul L. Berns 126,617,746 6,076,577 25,026,919 Matthew Fust 125,242,046 7,452,277 25,026,919 David Piacquad 126,878,899 5,815,424 25,026,919
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Neumora Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-27 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 2. The ratification of the selection by the audit committee of the board of directors of the Company (the “Board”) of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. The results of the vote were as follows: Votes For Votes Against Abstentions 157,623,815 53,613 43,814
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Neumora Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-27 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 3. The advisory vote on the compensation of the Company’s named executive officers. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 131,998,871 420,917 274,535 25,026,919
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Neumora Therapeutics, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2026-05-27 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 4. The advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers. The results of the vote were as follows: For One Year For Two Years For Three Years Abstentions Broker Non-Votes 124,682,414 23,968 7,948,592 39,349 25,026,919
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.